Allergan Agrees to $13.75 Million Deal with Tribe to Protect Restasis Patents

September 8, 2017: By Joan McKenna

Allergan-logoAllergan announced Sept. 8 that it has agreed to a $13.75 million deal with the Saint Regis Mohawk Tribe that transfers all FDA Orange Book-listed patents covering Restasis to the tribe and gives Allergan an exclusive license to the patents.

The move is designed to protect the patents, as Allergan faces increasing competition from developers of generic versions of its dry eye treatment.

Allergan was set to go before the US patent office Sept. 15 for an inter partes review by petitioners Mylan, Teva, and Akorn.

The tribe has sovereign immunity from patent challenges and will now file a motion to dismiss the inter partes review proceedings, Allergan said.

Bob Bailey, Allergan’s chief legal officer, said the tribe, located in Franklin County, New York, approached Allergan with the idea. Bailey said Allergan was impressed with the tribe’s thoughtful and enterprising approach, which would allow the tribe to achieve its goals of self-reliance and help it to address the most urgent needs in its community.

Under the deal, the tribe also is eligible to receive $15 million in annual royalties.

The deal has no affect on Allergan’s suit against Mylan, Teva Pharmaceuticals, Akorn, and Pfizer’s Inno Pharma division related to their abbreviated new drug applications for generic versions of Restasis. A five-day trial bench trial in the case just concluded in US District Court in Marshall, Texas.

Patents on Restasis run through Aug. 27, 2024. The drug was US FDA approved in 2003.

Allergan’s Restasis sales in 2017 totaled nearly $1.5 billion. However, Q2-2017 sales were about $354 million, a 9.4 percent decline over the same quarter last year due to pressure from Shire’s new Xiidra.

Also on Aug. 29, Allergan agreed to settle with generics drugmaker Famy Care, allowing Famy to market a Restasis generic in February 2024 or earlier if certain undisclosed circumstances are met.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023